Evidence map›Paper›PMID 42098446›Full record

ArticleNature chemistry2026

[2+2] Photocycloaddition reactions of sulfinylamines with alkenes to access β-sultam derivatives.

Yin Yuan, Xinyu Zhu, Zhixiao Cheng, Zijian Zhao, Ke Hu, Junliang Zhang, Junfeng Yang

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Nature chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Yin YuanState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China.
Xinyu ZhuHenan Institute of Advanced Technology, Zhengzhou University, Zhengzhou, China.
Zhixiao ChengState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China.
Zijian ZhaoState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China.
Ke HuSchool of Chemical Science and Engineering, Tongji University, Shanghai, China.ORCID http://orcid.org/0000-0002-0240-7192
Junliang ZhangState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China. junliangzhang@fudan.edu.cn.ORCID http://orcid.org/0000-0002-4636-2846
Junfeng YangState Key Laboratory of Green Chemical Synthesis and Conversion, Department of Chemistry, Fudan University, Shanghai, China. yangjf@fudan.edu.cn.ORCID http://orcid.org/0000-0001-5209-1301

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intermolecular [2+2] photocycloaddition reactions have emerged as a pivotal method for synthesizing four-membered cyclic compounds. However, no general, efficient protocol exists for accessing β-sultams or their analogues through intermolecular [2+2] photocycloaddition. Here we introduce an unconventional visible-light-mediated [2+2] photocycloaddition reaction between alkenes and sulfinylamines, facilitating the efficient synthesis of β-sultam derivatives that have garnered significant interest for their potential as covalent inhibitors in medicinal chemistry. Our approach features triplet energy transfer of sulfinylamines, enabling access to a broad range of β-sultams that were previously deemed inaccessible through conventional methods. Using a combination of experimental and computational techniques, we identify the origins of regio- and diastereo-selectivities, revealing the key factors influencing reaction efficiency. This method not only broadens the scope of available β-sultams and their derivatives but also highlights the potential of sulfinylamines as versatile reagents in organic synthesis.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.